Cargando…
Liposomal-delivery of phosphodiesterase 5 inhibitors augments UT-15C-stimulated ATP release from human erythrocytes()
The use of liposomes to affect targeted delivery of pharmaceutical agents to specific sites may result in the reduction of side effects and an increase in drug efficacy. Since liposomes are delivered intravascularly, erythrocytes, which constitute almost half of the volume of blood, are ideal target...
Autores principales: | Bowles, Elizabeth A., Feys, Dimitri, Ercal, Nuran, Sprague, Randy S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613235/ https://www.ncbi.nlm.nih.gov/pubmed/28955799 http://dx.doi.org/10.1016/j.bbrep.2017.09.002 |
Ejemplares similares
-
Liposomal delivery of a phosphodiesterase 3 inhibitor rescues low oxygen-induced ATP release from erythrocytes of humans with type 2 diabetes
por: Dergunov, Sergey A., et al.
Publicado: (2015) -
Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5
por: Adderley, Shaquria P., et al.
Publicado: (2011) -
Toward a Multiscale Description of Microvascular Flow Regulation: O(2)-Dependent Release of ATP from Human Erythrocytes and the Distribution of ATP in Capillary Networks
por: Goldman, Daniel, et al.
Publicado: (2012) -
Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases
por: Krivić, Hannah, et al.
Publicado: (2022) -
Purinergic signaling is enhanced in the absence of UT‐A1 and UT‐A3
por: Himmel, Nathaniel J., et al.
Publicado: (2020)